{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:36:50Z","timestamp":1780591010298,"version":"3.54.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tianjin Science &amp; Technology Plan Project","award":["17ZXMFSY00190"],"award-info":[{"award-number":["17ZXMFSY00190"]}]},{"name":"Tianjin Traditional Chinese Medicine Research Project","award":["2017003"],"award-info":[{"award-number":["2017003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Apatinib is a novel anti-angiogenic agent that targets vascular endothelial growth factor receptor-2, and is effective in patients with advanced lung cancer who are refractory to first-line chemotherapy. However, there are limited reports on concurrent apatinib therapy with iodine-125 radioactive seeds brachytherapy in elderly patients with advanced lung cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We describe the first reported case of a 70-year-old woman with advanced lung cancer (T3N3M1, stage IV) who received concurrent apatinib and iodine-125 radioactive seeds brachytherapy after the failure of platinum-based doublet chemotherapy<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed with left lower lung cancer with mediastinal lymph node metastasis by chest computed tomography.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Initially, apatinib alone was used as second-line cancer therapy. Subsequently, the patient received concurrent apatinib and iodine-125 radioactive seeds brachytherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient achieved partial response shortly after undergoing treatment with only apatinib. During the treatment, the tumor continued to respond to apatinib therapy, and the lung metastases were diminished eventually. However, a chest computed tomography scan showed a large cavity in the lung tumor. Thereafter, the patient received concurrent apatinib and iodine-125 radioactive seeds brachytherapy. Unfortunately, she died due to pulmonary infection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Apatinib alone may be a good second-line therapy for advanced lung cancer patients who are refractory to platinum-based doublet chemotherapy. However, its potential benefits, especially as combination therapy, need further investigation by future prospective clinical studies. Elderly patients with advanced lung cancer may benefit from concurrent apatinib with iodine-125 radioactive seeds brachytherapy when chemotherapy is not tolerated or effective. Further studies are needed to investigate the clinical outcomes and toxicities associated with concurrent apatinib and radiation therapy in patients with advanced lung cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021600","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T06:16:07Z","timestamp":1597299367000},"page":"e21600","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer"],"prefix":"10.1097","volume":"99","author":[{"given":"Yunchao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Yin","sequence":"additional","affiliation":[{"name":"Administration Department, Sinopharm Group Tianjin Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine"},{"name":"Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ccm.2011.08.005","article-title":"Pathology of lung cancer","volume":"32","author":"Travis","year":"2011","journal-title":"Clin Chest Med"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol"},{"issue":"(Suppl 15)","key":"R4-20230915","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1200\/jco.2012.30.15_suppl.7548","article-title":"A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens","volume":"30","author":"Zhang","year":"2012","journal-title":"J Clin Oncol"},{"key":"R5-20230915","first-page":"103","article-title":"Radiation dose escalation by percutaneous interstitial brachytherapy in locally advanced non-small cell lung cancer","volume":"51","author":"Sharma","year":"2009","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2015.09.006","article-title":"American Brachytherapy Society consensus guidelines for thoracic brachytherapy for lung cancer","volume":"15","author":"Stewart","year":"2016","journal-title":"Brachytherapy"},{"key":"R7-20230915","first-page":"123","article-title":"Clinical advances in the development of novel VEGFR2 inhibitors","volume":"2","author":"Fontanella","year":"2014","journal-title":"Ann Transl Med"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"R9-20230915","doi-asserted-by":"crossref","DOI":"10.1177\/1533033819825845","article-title":"Permanent iodine-125 seed implantation for the treatment of nonresectable retroperitoneal malignant tumors","volume":"18","author":"Li","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1278-3218(02)00286-X","article-title":"Brachytherapy in head and neck cancers","volume":"7","author":"Mazeron","year":"2003","journal-title":"Cancer Radiother"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/1748-717X-8-194","article-title":"Re-implantation after insufficient primary 125-i permanent prostate brachytherapy","volume":"8","author":"Putora","year":"2013","journal-title":"Radiat Oncol"},{"key":"R12-20230915","first-page":"504","article-title":"Combination of cryosurgery and iodine-125 seeds brachytherapy for lung cancer","volume":"4","author":"Niu","year":"2012","journal-title":"J Thorac Dise"},{"key":"R13-20230915","first-page":"237","article-title":"The efficacy and safety of iodine-125 brachytherapy combined with chemotherapy in treatment of advanced lung cancer: a meta-analysis","volume":"27","author":"Qiu","year":"2017","journal-title":"J Coll Physicians Surg Pak"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3892\/mco.2013.171","article-title":"Computed tomography fluoroscopy-guided percutaneous (125) I seed implantation for safe, effective and real-time monitoring radiotherapy of inoperable stage T1-3N0M0 non-small-cell lung cancer","volume":"1","author":"Li","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.lungcan.2007.12.016","article-title":"CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC)","volume":"61","author":"Martinez-Monge","year":"2008","journal-title":"Lung Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:19:46Z","timestamp":1694827186000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021600"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":15,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021600","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]}}}